Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: A meta-analysis by risk

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 11, 2008, Pages 1218-1223

  Halkes, P H A ^a   Gray, L J ^b   Bath, P M W ^b,f   Diener, H C ^c   Guiraud Chaumeil, B ^d   Yatsu, F M ^e   Algra, A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d CHU PURPAN   (France)

^e UNIVERSITY OF TEXAS   (United States)

^f NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; PLACEBO; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG EFFECT; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MONOTHERAPY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; DRUG COMBINATION; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE;

EID: 55249106449     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.143875     Document Type: Article

References (31)

1. Warlow CP. Secondary prevention of stroke. Lancet 1992;339:724-7.
2. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-9.
3. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255.
4. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
7. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
8. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
9. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-65.
10. Mohr JP, Thompson JLP, Lazar RM, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
11. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-16.
12. Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006;3:CD001342.
13. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115-24.
14. Guiraud-Chaumeil B, Rascol A, David J, et al. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapique controlé de 3 ans. Rev Neurol (Paris) 1982;138:367-85.
15. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
16. American-Canadian Co-operative Study group. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985;16:406-15.
17. Kaye JA. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell, Berkshire, Boehringer Ingelheim (internal report). 1990.
18. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997;151(Suppl):S1-77.
19. Algra A, van Gijn J, Koudstaal PJ. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 1999;66:557-9.
20. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-8.
21. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
22. Ariesen MJ, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006;37:134-8.
23. Kappelle LJ, van Latum JC, van Swieten JC, et al, for the Dutch TIA Trial Study Group. Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? J Neurol Neurosurg Psychiatry 1995;59:127-31.
24. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6.
25. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-8.
26. The Dutch TIA Trial Study Group. Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke. Stroke 1993;24:527-31.
27. Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005;24:1307-19.
28. Dippel DW, Koudstaal PJ. We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group. Stroke 1997;28:774-6.
29. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005;1:19-26.
30. Sacco RL, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005;62:403-8.
31. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.